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Abstract
Tuberculosis constitutes a serious public health problem because it has multi-resistant forms that require treatment 
that is both difficult and extensive. There is a need to develop new antimycobacterial compounds, and plants represent 
a source of therapeutic resources. This study analyzed antimycobacterial action in eight extracts from plants found 
in the Brazilian Cerrado. The results showed significant inhibitory concentrations in relation to Mycobacterium 
tuberculosis, especially from the extracts of Apuleia molaris and Ouratea spectabilis, both of which presented reduced 
cytotoxic effects. Fractionation revealed a hexane fraction of A. molaris with significant and promising activity 
regarding future in vivo assays. 
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Resumo
A tuberculose representa um sério problema de saúde pública diante as formas multirresistentes, tratamentos 
extensivos e dificuldades à adesão. Há necessidade em desenvolver novos compostos antimicobacterianos, sendo 
as plantas uma fonte de recursos terapêuticos. Este estudo analisou ação antimicobacteriana em oito extratos de 
plantas presentes no Cerrado. Os resultados demonstraram expressivas concentrações inibitórias para Mycobacterium 
tuberculosis com destaque para Apuleia molaris e Ouratea spectabilis, ambos apresentaram reduzidos efeitos citotóxicos, 
cujo fracionamento relevou uma fração hexânica de A. molaris com atividade significativa e promissora para futuros 
ensaios in vivo.
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1 Introduction
Tuberculosis (TB) is mainly caused by the Mycobac-
terium tuberculosis bacillus (PANDIT et al., 2015) and it 
represents a serious public health problem worldwide 
(BOTTGER, 2011). There were 10.4 million new ¬¬cases 
and 1.4 million deaths due to TB reported in 2015, which 
reflects an infectious disease with high mortality rates 
(WHO, 2016).
The high rates of incidence and prevalence of TB 
in developing countries have an impact on morbidity 
and mortality, particularly because the incidence of the 
human immunodeficiency virus (HIV) is also high (AL-
FFENAAR et al., 2017). 
Increased numbers of cases of MDR-TB (multidrug-re-
sistant tuberculosis) (PANDIT et al., 2015) and XDR-TB 
(extensively drug-resistant tuberculosis) (PARIDA et al., 
2015) have made it difficult to control this disease becau-
se the latter do not adequately correspond to treatment 
(SINGH et al., 2015), as well as presenting higher toxicity 
and treatment costs (TIBERI et al., 2017b).
There has been scant development of new drugs to 
treat TB. This represents a challenge and new research is 
required in relation to factors such as new mechanisms of 
action (SINGH and MIZRAHI, 2017), reduced treatment 
period (SANDGREN et al., 2009), increased effectiveness 
regarding resistant strains (TIBERI et al., 2017a), and 
reduced adverse effects of treatment (KUETE, 2010).
Natural products, especially plants, are capable of 
providing innovative structures for the formulation of 
new drugs (SANTHOSH and SURIYANARAYANAN, 
2013). They are important sources of bioprospecting 
for antimycobacterial compounds (PAULI et al., 2005), 
and trials involving plant extracts are increasingly more 
frequent (FIDELIS et al., 2014; MOLINA-SALINAS et 
al., 2010). 
The Brazilian Cerrado is a promising biome because 
it contains specimens with pharmacological potential 
(NOVAES et al., 2013), expressive phytophysiological 
heterogeneity, and floristic richness (SANO et al., 2010). 
The Cerrado contains more than 12,000 plant species, 
approximately 30% of which are endemic to the region 
(FORZZA et al., 2010).
The Cerrado is considered to be the planet’s richest 
tropical savannah in terms of biodiversity (SANO et 
al., 2010); it occupies an area of approximately 1,783 
million square kilometers, which represents 22% of the 
Brazilian territory (JEPSON, 2005). However, increasing 
levels of agribusiness have had negative impacts on this 
biodiversity and resulted in changes in the water cycle 
(SPERA et al., 2016).
The Cerrado is considered to be a hotspot in terms of 
biodiversity. It is a region with an exceptional concentra-
tion of endemic species which results from a great loss 
of natural areas (MITTERMEIER et al., 2004, MYERS et 
al., 2000). Its preservation is a priority, although in Brazil 
only 3% of this biome is legally protected by preservation 
areas (FRANÇOSO et al., 2015). 
Due to this urgent scenario, and the estimated phar-
macological potential within the Cerrado, this study 
analyzed specimens found in the Cerrado. There are 
currently few scientific studies regarding the antimy-
cobacterial activity of such specimens. 
2 Materials and Methods
2.1 Botanical Material
All the botanical material was collected from the 
Cerrado biome in the Brazilian state of Tocantins. The 
specimens were identified in the herbarium of the Federal 
University of Tocantins (UFT), Porto Nacional campus.
2.2 Preparation of extracts
The samples were dried at room temperature, ground 
in a knife mill, and packed in amber flasks to percolate 
in 70% (v/v) ethanol for 72 hours at 25 °C, protected 
from light.
The solutions were filtered and their solvents were 
removed using a rotary evaporator to concentrate the 
crude extracts. The extracts were lyophilized and stored 
at -20°C. 
2.3 Phytochemical screening
The processes of phytochemical identification, fractio-
nation and the production of the extracts were conducted 
at the UFT Phytochemical Laboratory. For the phyto-
chemical analysis, a qualitative, preliminary, prospection 
methodology was followed, based on the detection of 
some important constituents of the secondary metabolite 
groups (SIMÕES et al., 2007). 
2.4 Fractionation
The extracts with potential activity against Mycobac-
terium tuberculosis were fractionated. An aliquot of 5.0 g 
of each extract was solubilized in 100 mL of methanolic 
solution (MetOH:H2O) in a 4:1 ratio and then partitioned 
into a separatory funnel using solvent of increasing po-
larity: n-hexane (5 x 30 mL) and dichloromethane (5 x 30 
mL). The solvents were removed using a rotary evaporator 
and the extracts were lyophilized and packaged at -20°C. 
2.5 Microbiological assays 
The analysis of antimycobacterial activity was perfor-
med at the Central Laboratory of Public Health of Tocantins 
(LACEN-TO) using the MABA (microplate alamar blue 
assay) method described by Franzblau et al. (1998). The 
assays used the Mycobacterium tuberculosis, H37Rv standard 
strain, ATCC (American Type Culture Collection) 27294, 
which was provided by the Professor Hélio Fraga Reference 
Center/Fiocruz, Rio de Janeiro, Brazil.
The mycobacterial suspension (1:25), in 7H9 medium 
(4.7g of Middlebrook 7H9 broth base - Difco) with 10% 
ADC (albumin, dextrose and catalase), was prepared from 
the inoculum (H37Rv) on the No. 1 McFarland standard 
scale (3.2 x 106 CFU/mL). Rifampicin -RIF- (Sigma-Aldrich) 
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was chosen as the standard antibiotic.
The dried extracts were dissolved in Type I water 
containing 1% DMSO (dimethylsulfoxide) and subjected 
to sterile filtration (0.22 μm). These were adjusted to an 
initial concentration of 250 μg/mL, followed by two-fold, 
serial dilutions to a final concentration of 0.49 μg/mL. 
For the RIF, an initial concentration of 32 μg/mL and 
final concentration of 0.0625 μg/mL were used.  
The microbiological assays were run in triplicate 
using sterile, 96-well microplates, which were sealed and 
incubated for seven days at 37 °C. After this period, 30 
μL of 0.01% (w/v) resazurin was added to all the wells and 
re-incubated for 24 hours before the readings were taken.
The minimum inhibitory concentration (MIC) was 
determined as the lowest concentration of extract that 
prevented a change of color to pink. Extracts with MIC 
<100 μg/mL were considered to be promising regarding 
antimycobacterial activity according to the classification 
criteria adopted by Kuete (2010). 
2.6 Cytotoxicity Study
The extracts that were identified as having significant an-
timycobacterial activity (MIC <100 μg/mL) were evaluated for 
cytotoxicity. For these assays, the following two cell lines were 
used: LLC-MK2 (ATTC CCL-7) and Vero (ATCC CCL-81). 
Mosmann’s methodology (MOSMANN, 1983) was followed, 
using MTT (3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetra-
zolium bromide). The experiments were performed at the 
Laboratory of Parasitology of the Department of Clinical, 
Toxicological and Bromatological Analysis at the University 
of São Paulo (USP) in the city of Ribeirão Preto.
The cells were cultured in Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), streptomycin (100 μg/mL), penicillin (100 IU/mL) and 
amphotericin B (25 μg/mL). The cells were then incubated 
in a 5%, CO2 oven, under a humid atmosphere of 37 °C until 
80% confluence; they were subsequently diluted in phospha-
te-buffered saline (PBS) for 1 x 106 cells/mL. Cell viability was 
assessed using the Trypan blue exclusion method. 
In sterile, 96-well microplates, 200 μL of cell suspen-
sion (106 cells/mL) was pipetted into all orifices; after 48 
hours incubation half of this volume was discarded. The 
extracts then underwent serial, two-fold dilutions (500-
3.9 μg/mL): 100 μL of each concentration was pipetted 
into the wells using cellular carpet and then re-incubated 
for 24 hours. Subsequently, 50 μL of MTT (2.5 mg/mL) 
was added to all the wells, followed by a wait of three 
hours. Then, 50 μL of DMSO was added to dissolve the 
formazan blue crystals the absorbance was read at 570 
nm using a Stat Fax 2100 microplate spectrophotometer 
(Awareness Technology, Palm City, FL, USA). In the case 
of the untreated cells, the extracts were replaced with 
water and represented 100% viability, while Triton X-100 
solution was used as a positive control. 
2.7 Statistical Analysis 
The experiments were conducted in triplicate on 
alternate days. The IC50 (inhibitory concentration) value 
corresponds to 50% inhibition of cell growth, which was 
determined by a dose-response curve prepared using 
GraphPad Prism, version 5.0, Windows software. The 
analysis between the different groups was performed 
using the Student’s t-test method and the differences 
were considered significant when p ≤ 0.05. 
3 Results 
Eight hydroalcoholic extracts of plants from the Cerrado 
biome in Tocantins, Brazil were selected and evaluated for 
antimycobacterial activity, as shown in Table 1. 
The extracts of Apuleia molaris and Ouratea spectabilis 
Botanical species Vernacular Herbal registrationa Part extracted
b MICc (µg/mL)
Plathymenia reticulata Benth Vinhático 10.072 Bark (–)d
Ouratea spectabilis (Mart. Ex Engl.) Cabeça de negro 9.547 Bark 62.5
Galactia glauscescens Kunth Três folhas 10.070 Branches and leaves (–)d
Apuleia molaris Spruce ex Benth Grapia 9.614 Branches and leaves 62.5
Dipteryx alata Vogel Baru 9.687 Bark 125.0
Brosimum gaudichaudii Trécul. Inharé 10.068 Bark 125.0
Tabebuia caraíba (Mart.) Bureau Paratudo 9.680 Bark 125.0
Terminalia fagifolia Mart. Camaçari 10.842 Bark (–)d
a - specimens were identified in the herbarium of the UFT; b – 70% alcoholic extract (v/v); c – minimum inhibitory concentration; d - ab-
sence of antimycobacterial effect at a concentration of 250 μg/mL. Note: RIF presented MIC = 0.5 μg/mL.
Table 1 – Relationship of Cerrado plants used in the microbiological assays against M. tuberculosis H
37
Rv (ATCC 
27294) and their respective inhibitory concentrations.
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showed the most significant inhibitory concentrations 
(MIC <100 μg/mL), with promising antimycobacterial 
potential according to the classification criteria adopted 
by Kuete (2010). The other extracts produced moderate 
activity (100 <MIC ≤ 625 μg/mL) against the M. tuber-
culosis strain. Only the extracts with significant MICs 
were selected for the processes of phytochemical iden-
tification, cytotoxicity and partitioning, i.e. those lower 
than 100 μg/mL.
The phytochemical assays for A. molaris and O. spec-
tabilis showed positive indications in both extracts of 
the qualitative presence of saponins, tannins, phenols, 
flavonoids, steroids and triterpenoids.  
In relation to the cytotoxicity experiments involving 
Vero cells, the graph (FIGURE 1) of the log scale showed 
a growth curve of cell death as the concentration of the 
extracts increased.
Figure 1 – Cytotoxicity (IC
50
) for the crude extracts of 
O. spectabilis and A. molaris in relation to Vero cells        
(1.0 x 106 cells/mL).
The IC50 values were 192.0 μg/mL for A. molaris and 
217.2 μg/mL for O. spectabilis (FIGURE 1). There was no 
statistical difference between the paired data (t = 1.23, p 
= 0.26) and their curves showed a similar performance; 
thus, both extracts demonstrated mild levels of cytoto-
xicity in relation to Vero cells. 
The A. molaris extract presented a mild cytotoxic 
effect (IC50 = 95.2 μg/mL) and O. spectabilis presented 
moderate cytotoxicity (IC50 = 49.8 μg/mL) in relation to 
the LLC-MK2 cell line (FIGURE 2). Although there were 
distances between some points of the curve, in the case 
of the statistical analysis of the t-student test there was 
no significant difference between the assays (t = 2.23; p 
= 0.06). 
In the partitioning step, three different fractions were 
obtained for each sample, which were evaluated again for 
their antimycobacterial effect (TABLE 2). The fractions (HEX, 
DCM, MetOH) of O. spectabilis did not provide as good results 
as the crude extract, demonstrating a possible synergistic 
effect between the substances present in its composition.  
The hexanic fraction of A. moralis showed the best 
results regarding the ability to inhibit the H37Rv strain. 
It is likely that this fraction isolated apolar compounds 
of the steroid and terpenoid type, demonstrating efficacy 
against M. tuberculosis. 
Figure 2 – Cytotoxicity (IC
50
) for the crude extracts of    
O. spectabilis and A. molaris in relation to LLC-MK
2
 cells 
(1.0 x 106 cel/mL).
4 Discussion
The Fabaceae family is widely distributed in the Cer-
rado biome (NOVAES et al., 2013) and its representativity 
was also reflected in the percentage of species collected 
for this study; 50% of the samples belong to this family.
The significant antimycobacterial performance of 
the crude extracts of A. molaris and O. spectabilis are 
considered to be relevant (MIC ≤ 64 μg/mL) for phar-
macology (CANTRELL et al., 2001). This activity may be 
due to the presence of tannins, triterpenoids (NAYYAR 
and JAIN, 2005), flavonoids (MOLINA-SALINAS et al., 
2010) and saponins (WINK, 2008), as these are structural 
classes of metabolites known for their broad spectrum of 
antimicrobial activity (KUETE, 2010; SANTHOSH and 
SURIYANARAYANAN, 2013).
The presence of different functional groups in plant 
extracts allows a variety of mechanisms of action to occur, 
which reduces bacterial resistance (SINGH et al., 2015). 
Extract Fraction* Yield (%) MIC (µg/mL)
O. spectabilis
HEX 10.3 250.0
DCM 14.5 250.0
MetOH 22.7 125.0
A. molaris
HEX 16.2 31.25
DCM 22.8 250.0
MetOH 30.4 250.0
Table 2 – Minimal inhibitory concentrations (MIC) of 
different fractions obtained from the crude extracts 
of Ouratea spectabilis and Apuleia molaris against the             
M. tuberculosis strain. 
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The cell membrane is the main target and the majo-
rity of mutations are associated with its permeability 
(PARIDA et al., 2015). 
The methanolic fraction of O. spectabilis did not 
out-perform the results of its crude extract; however, it 
was the fraction with the best performance. This sample 
had high polarity and it is very likely to have contained 
isolated compounds of the flavonoid type. Extracts may 
contain substances that facilitate the adsorption of po-
lar compounds (WINK, 2008), which would explain the 
performance of this fraction.
The genus Ouratea, which is present in the Ochnacea 
family, is characterized as a source of flavonoids and 
biflavonoids (D’ARC FELICIO et al., 2001). Extracts of 
the Ouratea species contain biflavonoids that perform 
important biological activities, with antitumoral (FIDE-
LIS et al., 2014), antiviral (BRANDÃO et al., 2011) and 
antimicrobial (GANGOUÉ-PIÉBOJI et al., 2006) effects. 
Extracts of the Ouratea species have demonstrated mo-
derate effects regarding the inhibition of different gram 
positive, cocci species, especially for Staphylococcus 
aureus, as well as Candida albicans yeasts. 
Previous studies (MECINA et al., 2014; SIMONI et al., 
2002; VALADARES et al., 2003) have identified the presence 
of several types of flavonoids in relation to O. spectabilis, 
particularly biflavonoids (6,6´´-bigenkwanin; 7-7´´-dime-
toxi-agasthisflavona), which reflects a probable association 
between the antimycobacterial effect for this metabolic 
group in the methanolic fraction in the present study.
Regarding the evaluation of cytotoxicity, Simoni et al. 
(2002) and Brandrão et al. (2011) reported that extracts 
from O. spectabilis leaves had low cytotoxicity. This cor-
roborates with the results of the present study regarding 
the alcoholic extract of the bark, which was found to 
have a mild cytotoxic effect.
The hexane, apolar fraction of A. molaris showed a 
more significant effect in the present study: it was able to 
penetrate the mycobacterial cell wall, inhibit its growth 
and cause cell death. Mycobacteria have a hydrophobic 
cell wall that is rich in lipids (mycolic acids), which are 
generally susceptible to apolar compounds (NAYYAR and 
JAIN, 2005; PAULI et al., 2005), and this might explain 
the good performance of this fraction. 
There are few studies regarding the A. molaris species 
(synonym: A. leiocarpa), most of which are associated with 
morphological characterization (SOUZA REIS et al., 2016). 
Some of the existing studies have described antimalarial 
(MUÑOZ et al., 2000), antibiofilm (SILVA et al., 2015), 
anti-inflammatory and analgesic (RUPPELT et al., 1991) 
biological effects, whose properties are correlated with 
the presence of tannins, flavonoids (WOLLENWEBER and 
H. DIETZ, 1981), triterpenes and -amyrin (MUÑOZ 
et al., 2000).
Experiments conducted by Silva et al. (2015) in relation 
to A. leiocarpa fruit (synonym: A. molaris) demonstrated 
antibiofilm potential against Staphylococcus epidermidis, 
as well as a low toxicity in relation to Vero cells. This 
reinforces the promising character of this specimen and 
highlights the need for further studies to provide better 
chemical and biological characterization. 
Conclusion
The extracts of Ouratea spectabilis and Apuleia molaris 
showed chemical variation of secondary metabolites, 
which changed from polar (flavonoids) to apolar (steroids 
and triterpenes), suggesting different physiological ac-
tions in the face of mycobacterial attack.
The results of this study were expressive, especially 
when confirming that Apuleia molaris has potential an-
timycobacterial action and possesses low cytotoxic effect. 
Such characteristics suggest that it may be used as a 
future alternative in the treatment of tuberculosis. 
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